Navigation Links
Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents
Date:5/12/2008

Provides the Optimal Combination of Scaffolding, Deliverability and

Conformability

TEL AVIV, Israel, May 12 /PRNewswire/ -- Medinol is proud to announce that it has received CE Mark for its Presillion(TM) CoCr Coronary Stent, enabling physicians to treat coronary artery lesions with a technologically innovative flexible closed cell design stent.

Presillion(TM) preserves the superb scaffolding the unprecedented balance of flexibility and conformability identified with the NIRflex flexible closed cell design. The unique geometry of the Presillion(TM) complies with the long term needs of patients for both safety and efficacy in addition to ease of delivery for the physicians. The alternating rings provide simultaneously optimal flexibility and enhanced scaffolding. Dr. Kobi Richter, chairman of the board and chief technology officer of Medinol says, "Cobalt Chromium enables us to reduce the strut thickness and overall cell size by up to 25% compared to stainless steel while retaining superior scaffolding through the unique flexible closed cell design; this material also maintains a much higher fatigue resistance and radiopacity than the common stainless steel stents."

"Medinol is proud to introduce a new family of stent systems to the market, the first of which is the Presillion(TM). By utilizing its expertise and IP Medinol is proving itself once again as a leading developer, designer and manufacturer of stents and stent systems," says Dr. Judith Richter, chief executive officer for Medinol.

Medinol partnered with Cordis, a Johnson and Johnson company, last year, and will be distributing the Presillion globally. "We are happy that we are able to enrich Cordis's Cath Lab Cubed offer to market," says Dr. Richter.

Recent research recognized the value of Bare Metal Stents and the growing versatility of treatments of complex coronary artery disease. The introduction of the Presillion enhances the physicians' ability to choose the most suitable stent for each patient and the long term benefits provided for each individual vessel and lesion.

The Presillion comes in diameters ranging from 2.5-4.0 mm. and in lengths ranging from 8-32 mm. The Presillion stent system and can be used to treat various lesion types: de novo, restenotic lesions, total occlusions, bifurcations, and acute myocardial infarction.

Medinol continues setting new standards in the stenting industry through design innovation and advance technology manufacturing methods. Medinol is constantly enhancing its technology and producing stenting solutions for: coronary and vascular systems, bifurcation stenting and biliary stenting. Medinol is currently developing advanced technology stents and additional therapeutic solutions for the treatment of vascular disease that will be introduced to the market in the near future.

Contact:

Tamar Hadar

Senior Director, Global Sales & Marketing

Medinol Ltd.

Office: +972-3-7679000 ext. 256

Tamar.Hadar@MEDINOL.COM


'/>"/>
SOURCE Medinol Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
2. Strykers Biotech Division Receives FDA Warning Letter
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
7. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
10. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
11. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):